3Damiani JM, Sweet BV, Sohoni P. Melatonin: An option for managing sleep disorders in ehildren with autism spectrum dis- order [J]. AmJ HealthSyst Pharm,2014,71(2):95-101.
4Andersen IM, Kaezmarska J, McGrew SG, et al. Melatonin for insomnia in children with autism spectrum disorders [J]. J Child Neurol,2008,23(5) :482-485.
5Hardeland R. Melatonin metabolism in the eentral nervous system [J]. Curt Neuropharmaeol, 2010,8(3) : 168- 181.
6De Berardis D, Brucchi M, Serroni N, et al. Successful use of agomelatine in the treatment of major depression in a woman taking tamoxifen: a case report[J]. Clin Neuropharmaeol, 2014,37(1) :31-33.
7Millan MJ, Broeco M, Gobert A, et al. Anxiolytic properties of agomelatine, an antidepressant with melatoninergie and se- rotonergic properties: role of 5-HTzc receptor blockade [J]. Psyehopharmaeology(Berl), 2005,177 (4) : 448- 458.
8Smeraldi E, Delmonte D. Agornelatine in depression I-J]. Ex- pert Opin Drug Saf,2013,12(6) :873-880.
9Lejoyeux M, Matharan S, de Bodinat C. How to switeh to ag- omelatine after an unsuecessful try with paroxetine or ven- lafaxine[J]. CNS Speetr, 2013,13 : 1 - 10.
10Guaiana G, Gupta S, Chiodo D, et al. Agomelatine versus other antidepressive agents for major depression [J]. Cochrane Database Syst Rev, 2013,12 :CD008851.
二级参考文献57
1AUDINOT V, BONNAUD A, GRANDCOLAS L, et al. Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors [J]. Biochem Pharmacol, 2008, 75(10): 2007-2019.
2MILLAN M J, GOBERT A, LEJEUNE F, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5- hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergie and adrenergic pathways [J]. Pharmacol Exp Ther, 2003, 306(3): 954-964.
3PAPP M, GRUCA P, BOYER PA, et al. Effect of agomelatine in the chronic mild stress model of depression in the rat [J].Neuropsychopharmacology, 2003, 28(4): 694-703.
4MILLAN MJ, BROCCO M, GOBERT A, et ol. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties : role of 5-HT2C receptor blockade[J]. Psychopharmacology (Berl), 2005, 177(4): 448-458.
5BREMNER JD, NARAYAN M, ANDERSON ER, et al. Hippocampal volume reduction in major depression [J]. Am J Psychiatry, 2000, 157(1) : 115-118.
6FUCHS E, FLUGGE G, CZEH B. Remodeling of neuronal networks by stress[J]. Front Biosci, 2006, 11 : 2746-2758.
7DUMAN RS, MONTEGGIA LM. A neurotrophic model for stress related mood disorders [J]. Biol Psychiatry, 2006, 59 (12) : 1116-1127.
8BANASR M, SOUMIER A, HERY M, et al. Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis[J]. Biol Psychiatry, 2006, 59(11): 1087-1096.
9REDMAN JR, GUARDIOLA-LEMAITRE B, BROWN M, et ol. Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms [J]. Psychopharmaeology (Bed), 1995, 118(4): 385-390.
10MAILLIET F, AUDINOT V, MALPAUX B, et al. Molecular pharmacology of the ovine melatonin receptor: comparison with recombinant human MT1 and MT2 receptors [J]. Bioch Pharmacol, 2004, 67(4): 667-677.
5TARDITO D,M0 LTENI R,P0 P0 LI M, et al. Synergisticmechanisms in volved in the antidepressant effects of agomelatine [J]. Eur Neuropsychopharmacol, 2012, 22(Suppl 3) :482-486.
6SINGH S P, SINGH V,KAR N.Efficacy of agomelatine inmajor depressive disorder: meta-αnalysis and appraisal [J].Int J Neuropsychophamiacol,2012,15(3) :417-428.
7MARTINOTTI G,SEPEDE G, GAMBI F, et al.Agomelatineversus venlafaxine XR in the treatment of anhedonia inmajor depressive disorder : a pilot study [J]. J ClinPsychopharmacol,2012,32(4) :487-491.
8SHU L, SULAIMAN A H, HUANG Y S, et al.Comparableefficacy and safety of 8 weeks treatment with agomelatine25-50 mg, or fluoxetine 20-40 mg, in Asian out-patientswith major depressive disorder[J] .Asian J Psychiatr,2014,8(2) :26-32.
9CORRUBLE E , DE BODINAT C, BELAIDI C, et al.Efficacyof agomelatine and escitalopram on depression, subjectivesleep and emotional experiences in patients with majordepressive disorder: a 24-wk randomized, controlled,double-blind trial [J]. Int J Neuropsychophamiacol,2013,16(10) :2219-2234.
